Overview

A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

Status:
Completed

Trial end date:
2019-06-01

Target enrollment:

Participant gender:

Summary

Evaluating efficacy & safety of lacosamide versus Placebo in a blinded fashion as add-on Therapy for Primary Generalized Tonic-clonic (PGTC) seizures in subject 4 years of age or greater with idiopathic generalized epilepsy currently taking 1 to 3 antiepileptic drugs. Maximum duration of study drug administration is 28 weeks. Eligible subjects may choose to enter the open-label extension study after completion.

Phase:

Phase 3

Details

Lead Sponsor:

UCB BIOSCIENCES, Inc.

Collaborator:

Pharmaceutical Research Associates

Treatments:

Lacosamide
Pharmaceutical Solutions